Clinical Trial Detail

NCT ID NCT02120469
Title Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

triple-receptor negative breast cancer

Therapies

Eribulin + Everolimus

Age Groups: adult

No variant requirements are available.